BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16180963)

  • 1. Atypical antipsychotics: considerations for Medicaid coverage.
    Surles RC
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S248-53. PubMed ID: 16180963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical antipsychotics and the burden of disease.
    Simpson GM
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S235-41. PubMed ID: 16180961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of atypical antipsychotics on outcomes of care in schizophrenia.
    Joyce AT; Harrison DJ; Loebel AD; Ollendorf DA
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S254-61. PubMed ID: 16180964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of bipolar mania with atypical antipsychotics.
    Chengappa KN; Suppes T; Berk M
    Expert Rev Neurother; 2004 Nov; 4(6 Suppl 2):S17-25. PubMed ID: 16279862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
    Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
    Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicaid policies to contain psychiatric drug costs.
    Koyanagi C; Forquer S; Alfano E
    Health Aff (Millwood); 2005; 24(2):536-44. PubMed ID: 15757941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managed care's atypical response. New antipsychotics show promise, but are they getting into enough hands?
    Waldron T
    Behav Healthc Tomorrow; 1999 Apr; 8(2):28-31. PubMed ID: 10351297
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.
    Eaddy M; Grogg A; Locklear J
    Clin Ther; 2005 Feb; 27(2):263-72. PubMed ID: 15811492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.
    Valuck RJ; Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R;
    Curr Med Res Opin; 2007 Oct; 23(10):2567-76. PubMed ID: 17848204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.